Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 106 to 120 of 233 results for children's cancer

  1. Artificial intelligence technologies to aid contouring for radiotherapy treatment planning: early value assessment (HTE11)

    Early value assessment (EVA) guidance on artificial intelligence technologies to aid contouring for radiotherapy treatment planning in people having external be...

    Health technology evaluation
    Published
    27 September 2023
    View recommendations

    Sections for HTE11

  2. Setmelanotide for treating obesity caused by LEPR or POMC deficiency (HST21)

    Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity caused by LEPR or POMC deficiency in people 6 years and over.

    Highly specialised technologies guidance
    Published
    6 July 2022
    View recommendations

    Sections for HST21

  3. Mifamurtide for the treatment of osteosarcoma (TA235)

    Evidence-based recommendations on mifamurtide (Mepact) for treating osteosarcoma in people aged 2 to 30 years.

    Technology appraisal guidance
    Published
    26 October 2011
    View recommendations

    Sections for TA235

  4. Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (TA308)

    Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in adults.

    Technology appraisal guidance
    Published
    26 March 2014
    View recommendations

    Sections for TA308

  5. Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)

    Summary of the evidence on oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia to inform local NHS planning and decision-making

    Evidence summary
    Published
    29 January 2013

  6. Indicator advisory committee members

    Biographies and interests register for the indicator advisory committee

  7. Healthy start vitamins: special report on cost effectiveness (ECD5)

    Healthy start vitamins: special report on cost effectiveness

  8. Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay) (DG18)

    Evidence-based recommendations on procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay)

    Diagnostics guidance
    Published
    7 October 2015

    Sections for DG18

  9. Tegaderm CHG securement dressing for vascular access sites (MIB231)

    NICE has developed a medtech innovation briefing (MIB) on Tegaderm CHG securement dressing for vascular access sites .

    Medtech innovation briefing
    Published
    27 October 2020

  10. Committee D members

    Find out more about NICE technology appraisals advisory committee D members

  11. Pelvic floor dysfunction: prevention and non-surgical management (NG210)

    This guideline covers the prevention, assessment and non-surgical management of pelvic floor dysfunction in women aged 12 and over. It aims to raise awareness and help women to reduce their risk of pelvic floor dysfunction. For women who have pelvic floor dysfunction, the guideline recommends interventions based on their specific symptoms.

    NICE guideline
    Published
    9 December 2021
    View recommendations

    Sections for NG210

  12. Chronic anal fissure: botulinum toxin type A injection (ESUOM14)

    Summary of the evidence on botulinum toxin type A injection for treating chronic anal fissure to inform local NHS planning and decision-making

    Evidence summary
    Published
    25 June 2013

  13. MRI-based technologies for assessing non-alcoholic fatty liver disease (DG50)

    Evidence-based recommendations on MRI-based technologies for assessing non-alcoholic fatty liver disease

    Diagnostics guidance
    Published
    12 January 2023
    View recommendations

    Sections for DG50

  14. Committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  15. Medicines management in care homes (QS85)

    This quality standard covers managing medicines safely and effectively in care homes. It includes processes for prescribing, handling and administering medicines for adults, young people, and children living in care homes. It also includes providing care and support relating to medicines. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    25 March 2015
    View quality statements

    Sections for QS85